< Back to conference archives
Archive
About the 2022 Combination Products Summit
A summit focused on solutions for a dynamic industry with evolving regulations.
The Association of Food and Drug Officials (AFDO) and the Regulatory Affairs Professionals Society (RAPS) have come together to support sharing, collaboration, and learning across the global healthcare products community. With a focus on fostering open discussions of the most pressing issues facing the industry, the AFDO/RAPS Healthcare Products Collaborative will carry on Xavier Heath’s legacy of delivering the Combination Products Summit.
The AFDO/RAPS Healthcare Products Collaborative combination products community continues to be led by top FDA officials and worldwide industry leaders who built the framework for the regulatory landscape of combination products. This global community drives innovation and navigates the complexities specific to the world of combination products, resulting in the delivery of safe, effective, and high-quality products to the patients who need them.
And all of these exciting discussions come to life at the Combination Products Summit!
Hot topics from the 2022 conference:
1
From the Desk of the Office of Combination Products – Strategic Priorities
2
EU MDR – What is “Significant Change” and What You Need to Know About Notified Body Opinions
3
Use of Medical Devices and Digital Health Technologies in Drug Programs
4
FDA Fireside Chat – A panel of all FDA speakers take your questions
2022 Sponsors
Gold Sponsor
Silver Sponsor
Meet The New 2022 Conference Facilitators
The Association of Food and Drug Officials (AFDO) and the Regulatory Affairs Professionals Society (RAPS) have come together to support sharing, collaboration, and learning across the global healthcare products community. With a focus on fostering open discussions of the most pressing issues facing the industry, the AFDO/RAPS Healthcare Products Collaborative will carry on Xavier Health’s legacy of delivering the MedCon Conference.
“Almost a perfect meeting of minds between academia, regulatory agencies, and industry thought leaders to serve the only purpose – safety and public health in combination products.”
— Khaudeja Bano, M.D., Executive Medical Director, Combination Product Safety Head, Global Patient Safety, GRAAS, Research and Development, Amgen